Inhibition of platelet function by contrast media: iopamidol and ioxaglate versus iothalamate. Work in progress.
The effects of an ionic contrast agent, meglumine iothalamate (Conray-60), and two newer low-osmolality radiographic contrast media, sodium meglumine ioxaglate (Hexabrix) and iopamidol (B-15,000), on platelet aggregation and secretion responses were studied. All three agents inhibited platelet responses during stimulation with adenosine diphosphate (ADP), epinephrine, and collagen. Platelet function was inhibited by iothalamate at concentrations of 11 mg iodine/ml and above, and by the newer agents at concentrations above 30 mg iodine/ml. Addition of exogenous calcium decreased the iothalamate-induced inhibition of aggregation but did not improve dense granule secretion. There was no consistent effect of exogenous calcium on platelet inhibition by iopamidol and ioxaglate. These studies indicate that the newer agents inhibit platelet function less than iothalamate does, and that chelation of Ca2+ may not be the major mechanism of platelet inhibition by contrast agents.
D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000097:blood; D003287:Contrast Media / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007479:Iopamidol; D007482:Iothalamate Meglumine / Q000009:adverse effects; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives; D007485:Ioxaglic Acid; D010974:Platelet Aggregation / Q000187:drug effects*; D012701:Serotonin / Q000097:blood*; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007483:Iothalamic Acid; D012701:Serotonin; D007479:Iopamidol; D002118:Calcium; D007482:Iothalamate Meglumine; D007485:Ioxaglic Acid